Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT00557011 is registered in ClinicalTrials.gov with New River Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
- Lead sponsor
- New River Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- December 31, 2004
- Enrollment
- 52 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.